(August 27, 2025, Shanghai, China）— Recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; SSE: 600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has entered into a License Agreement with Sitala, a UK-based biotech company focused on developing innovative drugs for inflammation and autoimmune diseases. Under the agreement, Fosun Pharma Industrial will grant Sitala exclusive rights to develop, manufacture, and commercialize the small molecule inhibitor FXS6837 and products containing this active ingredient globally (except Chinese Mainland, Hong Kong SAR and Macau SAR). The licensed field includes the diagnosis and treatment of human and animal diseases. Fosun Pharma will retain the rights to develop, manufacture, and commercialize FXS6837 in Chinese Mainland, Hong Kong SAR and Macau SAR.

Under the agreement, Sitala will pay Fosun Pharma up to USD190 million including upfront payment, development and launch milestone payments. Additionally, Fosun Pharma will receive shares of Sitala valued at USD5million for zero consideration. In the future, based on the achievement of annual net sales of the licensed product in the licensed territory, Sitala will pay Fosun Pharma up to USD480 million in sales milestone payments as stipulated.

FXS6837 is a small molecule inhibitor with independent intellectual property right owned by Fosun Pharma, intended for the treatment of diseases in the field of immunomodulation. As of now, FXS6837 is in clinical trials in Chinese Mainland for relevant indications.

As of July 2025, the Group had invested approximately RMB 120 million (unaudited) in total in the research and development (the “R&D”) of FXS6837 at this stage. According to the latest data^[1] from IQVIA MIDASTM, the sales of major drugs for related diseases amounted to approximately US$3.8 billion in 2024.

Fosun Pharma always takes innovation as a core driving force in its development. Fosun Pharma has established a diversified and multi-level innovative model that integrates independent R&D, co-development, licensing, fund incubation, and industrial investment.The Company continuously enhances its capabilities across four key technology platforms: antibodies, ADCs, cell therapy, and small molecules, accelerating the translation of innovative technologies and products. Focusing on core therapeutic areas including solid tumors, hematologic malignancies and Immune-inflammatory disorders, Fosun Pharma has gradually built a high-value pipeline portfolio and is actively expanding into chronic diseases (cardiovascular, renal, and metabolic) and the neurological field.

In the field of innovative drugs, since 2019, Fosun Pharma has obtained approvals for 12 innovative drugs and biosimilars developed in-house or through licensing, and successfully secured the commercialization rights in Chinese Mainland for 8 innovative drugs.

In the first half of 2025, Fosun Pharma had four innovative products covering five indications approved in China, the EU, and other regions, including the first independently developed small molecule innovative drug Luvometinib Tablets (Chinese trade name:复迈宁^®); the innovative small molecule CDK4/6 inhibitor Fovinaciclib Citrate Capsules (Chinese trade name:复妥宁^®); the world’s first phosphate absorption inhibitor Tenapanor Hydrochloride Tablets (Chinese Trade name:万缇乐^®), approved in Chinese Mainland; and the anti-PD-1 monoclonal antibody (mAb) serplulimab injection approved in the EU, UK, India and other countries/regions, becoming the first PD-1 mAb approved in the EU for the treatment of extensive-stage small cell lung cancer (ES-SCLC). These achievements highlight both the innovation value of Fosun Pharma’s pipeline and the significant progress in its globalization strategy. In August, following the successful overseas licensing of a DPP-1 inhibitor, Fosun Pharma once again achieved a milestone by overseas licensing another small molecule inhibitor, FXS6837. These business development transactions not only bring financial returns, but also demonstrate international recognition of Fosun Pharma’s R&D capabilities, further empowering its ongoing innovation drive.

For over 30 years since its establishment, Fosun Pharma has remained a patient-centric approach, address unmet clinical needs and continuously strengthening its R&D. Looking ahead, Fosun Pharma will keep deepening innovation transformation and global expansion, striving to become a global leader in healthcare innovation and integration and creating better health for families worldwide.

***

[1]Data provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world.